Multicenter evaluation of the in vitro activity of six broad-spectrum β-lactam antimicrobial agents in Puerto Rico

Diagnostic Microbiology and Infectious Disease

Volumn 30, Issue 2, 1998, Pages 113-119

  Group, ^c   Doern, Gary V ^a   Jones, Ronald N ^a   Pfaller, Michael A ^a   Erwin, Meridith ^b   Ramirez Rhonda, Carlos ^b  

^a UNIVERSITY OF IOWA   (United States)

^b VA MEDICAL CENTER   (Puerto Rico)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZTREONAM; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CEPHALOSPORINASE; IMIPENEM; MEROPENEM; PENICILLIN DERIVATIVE; PIPERACILLIN; TAZOBACTAM;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; CITROBACTER FREUNDII; CONTROLLED STUDY; ENTEROBACTER; ENTEROBACTERIACEAE; ESCHERICHIA COLI; EVALUATION AND FOLLOW UP; HOSPITAL LABORATORY; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PUERTO RICO; QUALITY CONTROL; SERRATIA; STAPHYLOCOCCUS;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, MICROBIAL; GRAM-NEGATIVE AEROBIC RODS AND COCCI; GRAM-POSITIVE COCCI; HUMANS; MICROBIAL SENSITIVITY TESTS; PUERTO RICO;

EID: 0345516008     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(97)00160-0     Document Type: Article

References (32)

1. Barradell LB, Bryson HM. Cefepime a review of its antibacterial activity, pharmacokinetic properties and therapeutic use . Drugs. 47:1994;471-505.
2. Bolmstrom A, Arvidson S, Ericson M, Karlsson A (1988) A novel technique for direct quantification of antimicrobial susceptibility of microorganisms (Abstr. 1209). In: 28th Interscience Conference Antimicrobial Agents and Chemotherapy, Los Angeles, CA, 1988. Washington, DC: American Society for Microbiology, 1988.
3. Brown DFJ, Brown L. Evaluation of the E-test a novel method of quantifying antimicrobial activity . J Antimicrob Chemother. 27:1991;185-190.
4. Colombia Antimicrobial Resistance Study Group, Jones RN, Salazar JC, Pfaller MA, Doern GV, Lozano F (1997) Multi-center evaluation of the antimicrobial activity for six broad-spectrum β-lactams in Colombia using the E-test method. Diagn Microbiol Infect Dis. In press.
5. Cunha BA, Gill MV. Cefepime. Med Clin North Am. 79:1995;721-742.
6. Fung-Tomc J, Dougherty T, DeOrio F, Simich-Jacobson V, Kessler RE. Activity of cefepime against ceftazidime- and cefotaxime-resistant Gram-negative bacteria and its relationship to β-lactamase levels. Antimicrob Agents Chemother. 33:1989;489-502.
7. Gradelski E, Fung-Tomc J, Huczko E, Kessler RE. Development of resistance in Pseudomonas aeruginosa to broad-spectrum cephalosporins via step-wise mutations. J Antimicrob Chemother. 32:(suppl B):1993;75-80.
8. Grassi GG, Grassi C. Cefepime Overview of activity in vitro and in vivo . J Antimicrob Chemother. 32:(suppl B):1993;87-94.
9. Hancock REW, Bellido F. Factors involved in the enhanced efficacy against Gram-negative bacteria of fourth generation cephalosporins. J Antimicrob Chemother. 29:(suppl A):1992;1-6.
10. Jacoby GA, Carreras I. Activities of β-lactam antibiotics against Escherichia coli strains producing extended-spectrum β-lactamases. Antimicrob Agents Chemother. 34:1990;858-862.
11. Jacoby GA, Han P. Detection of extended-spectrum β-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli. J Clin Microbiol. 34:1996;908-911.
12. Jones RN, Fuchs PC. Activity of cefepime (BMY 28142) and cefpirome (HR 810) against Gram-negative bacilli resistant to cefotaxime or ceftazidime. J Antimicrobial Chemother. 23:1989;163-165.
13. Jones RN, Marshall SA. Antimicrobial activity of cefepime tested against Bush group 1 β-lactamase-producing strains resistant to ceftazidime. Diagn Microbiol Infect Dis. 19:1994;33-38.
14. Kessler RE, Bies M, Buch RE, Chisholm DR, Pursiano TA, Tsai YH, Misiek M, Price KE, Leitner F. Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum β-lactam antibiotics. Antimicrob Agents Chemother. 27:1985;207-216.
15. Kessler RE, Fung-Tomc J. Susceptibility of bacterial isolates to β-lactam antibiotics from U.S. clinical trials over a 5-year period. Am J Med. 100:(suppl 6A):1996;13S-19S.
16. Knapp CC, Washington JA. Activity of cefepime, ceftazidime, and ceftizoxime against mutants of Enterobacteriaceae and Pseudomonas aeruginosa derepressed for class I β-lactamase. J Antimicrob Chemother. 24:1989;1011-1012.
17. Knothe H, Shah P, Kremery V, Anatal M, Mitsuhaski S. Transferable resistance to cefotaxime, cefoxitin, cefamandole, and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection. 11:1983;315-317.
18. Livermore DM. β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev. 8:1995;557-584.
19. Moberg CL, Dubos R. A harbinger of microbial resistance to antibiotics. Microbial Drug Resist. 2:1996;287-297.
20. Monnet DL, Biddle JW, Edwards JR, Culver DH, Tolson JS, Martone WJ, Tenover FC, Gaynes RP. Evidence of interhospital transmission of extended-spectrum β-lactam-resistant Klebsiella pneumoniae in the United States, 1986 to 1993. Infect Control Hosp Epidemiol. 18:1997;492-498.
21. National Committee for Clinical Laboratory Standards (1997) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: Approved standard M7-A4. Villanova, PA: NCCLS.
22. Neu HC, Chin NX, Jules K, Labthavikul P. The activity of BMY 28142, a new broad spectrum β-lactamase stable cephalosporin. J Antimicrob Chemother. 17:1986;441-452.
23. Philippon A, Labia R, Jacoby G. Extended-spectrum β-lactamases. Antimicrob Agents Chemother. 33:1989;1131-1136.
24. Sader HS, Pfaller MA, Jones RN (1994) Prevalence of important pathogens and the antimicrobial activity of parenteral drugs at numerous medical centers in the United States. II. Study of the intra- and interlaboratory dissemination of extended-spectrum β-lactamase-producing Enterobacteriaeae. Diagn Microbiol Infect Dis 20:203-208.
25. Sanders CC. Cefepime The next generation? Clin Infect Dis. 17:1993;369-379.
26. Sykes RB, Matthew M. The β-lactamases of Gram-negative bacteria and their role in resistance to β-lactam antibiotics. J Antimicrob Chemother. 2:1976;115-157.
27. Thomson K (1997) β-Lactamases of Gram-negative pathogens: New and unanticipated problems. Infect Med. In press.
28. Thornsberry C, Brown SD, Yee YC, Bouchillon SK, Marler JK, Rich I. In vitro activity of cefepime and other antimicrobials Survey of European isolates . J Antimicrob Chemother. 32:(suppl B):1993;31-54.
29. Thornsberry C, Yee YC. Comparative activity of eight antibiotics against clinical bacterial isolates from the United States Broth microdilution (MicroScan) and the E-test methods . Am J Med. 100:(suppl 6A):1996;26S-38S.
30. Toye BW, Scriver SR, Low DE. Canadian survey of antimicrobial resistance in Klebsiella spp. and Enterobacter spp. J Antimicrob Chemother. 32:(suppl B):1993;81-86.
31. Tsuji A, Maniatis A, Bertram MA, Young LS. In vitro activity of BMY 28142, in comparison with those of other β-lactam antimicrobial agents. Antimicrob Agents Chemother. 27:1985;515-519.
32. Venezuela Antimicrobial Resistance Study Group, Pfaller MA, Jones RN, Doern GV (1997) Multi-center evaluation of the antimicrobial activity for six broad-spectrum β-lactams in Venezuela using the E-test method. Diagn Microbiol Infect Dis. In press.